Patent Assignment
Reel/Frame 075576/0880
Security Interest
Recorded: 2026-05-08
Pages: 97
Assignor
RIGEL PHARMACEUTICALS, INC.
Executed: 2026-05-05
Assignee
MIDCAP FUNDING IV TRUST
7255 WOODMONT AVENUE, SUITE 300, BETHESDA, MARYLAND, 20814
Covered Properties
(310)
Methods of Treating or Preventing Autoimmune Diseases with 2, 4-Pyrimidinediamine Compounds
2,4-Pyrimidinediamine Compounds for Treating or Preventing Autoimmune Diseases
2,4-Pyrimidinediamine Compounds for Treating or Preventing Autoimmune Diseases
2,4-Pyrimidinediamine Compounds and their Uses
Modulators of angiogenesis and tumorigenesis
Ubiquitin Ligase Inhibitors
Quinoline Compounds and Their Uses
Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
Heterocyclic Compounds Having an Oxadiazole Moiety and Hydro Isomers Thereof
Rhodanine Compositions for Use as Antiviral Agents
2-Substituted Quinoline Compounds and Their Uses
Methods for Cyclizing Synthetic Polymers
Heterotricyclic Compounds for Use as Hcv Inhibitors
Stereoisomers and Stereoisomeric Mixtures of 1-(2,4-Pyrimidinediamino)-2-Cyclopentanecarboxamide Synthetic Intermediates
Cycloalkyl Substituted Pyrimidinediamine Compounds and Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds and Their Uses
Cycloalkyl Substituted Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4 Pyrimidinediamine Compounds and Their Uses
Patent:
7,563,892 →
Application:
11/539,074 →
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
Patent:
48,898 →
Application:
16/291,992 →
Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and Their Uses
Stereoisomerically Enriched N-Protected Beta-Lactams Using Candida Antarctica
Benzisothiazoles Useful for Treating or Preventing Hcv Infection
Kinase Inhibitors and Their Uses
Kinase Inhibitors and Their Uses
Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties and Their Uses
Pyrimidine-2,4-Diamines and Their Uses
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Methods of Treating Cell Proliferative Disorders
Methods of Treating Cell Proliferative Disorders
Methods and Compositions for Treating Degenerative Bone Disorders
Triazole Derivatives Useful as Axl Inhibitors
Identification of Pharmacophores from Co-Crystals of Spleen Tyrosine Kinase (Syk) and Syk Ligands
Patent:
7,962,290 →
Application:
11/651,363 →
Pinane-Substituted Pyrimidinediamine Derivatives Useful as Axl Inhibitors
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Shrna Library
Diaminothiazoles Useful as Axl Inhibitors
N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use
N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use
N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Bicyclic Aryl and Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bicyclic Aryl and Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Aryl and Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Aryl and Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Aryl Substituted Triazoles and Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Aryl Substituted Triazoles and Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
N3-Heteroaryl Substituted Triazoles and N5-Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
N3-Heteroaryl Substituted Triazoles and N5-Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Substituted Triazoles Useful as Axl Inhibitors
Substituted Triazoles Useful as Axl Inhibitors
Substituted Triazoles Useful as Axl Inhibitors
Wet Granulation Using a Water Sequestering Agent
Wet Granulation Using a Water Sequestering Agent
Wet Granulation Using a Water Sequestering Agent
Ampk-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide and Amine Compounds and Methods for Using the Same
Ampk-Activating Piperidinyloxy-Substituted 2,3-Dihydro-1H-Indene-1-Amine Compounds and Pharmaceutical Compositions Including the Same
Carboxamide, Sulfonamide and Amine Compounds and Methods for Using the Same
Carboxamide, Sulfonamide and Amine Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Carboxamide Compounds and Methods for Using the Same
Use of 2,4-Pyrimidinediamines For the Treatment of Atherosclerosis
Pyrimidine-2-Amine Compounds and Their Use as Inhibitors of Jak Kinases
Tricyclic Carbamate Jak Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Polycyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Bridged Bicyclic Heteroaryl Substituted Triazoles Useful as Axl Inhibitors
Synthesis of 2,4-Pyrimidinediamines
Synthesis of 2,4-Pyrimidinediamines
Synthesis of 2,4-Pyrimidinediamines
Protein Kinase C Inhibitors and Uses Thereof
Axl Inhibitors for Use in Combination Therapy for Preventing, Treating or Managing Metastatic Cancer
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Patent:
47,396 →
Application:
14/918,353 →
Compounds and Method for Treating Autoimmune Diseases
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Compositions and Methods for Inhibition of the Jak Pathway
Pyrimidinediamine Kinase Inhibitors
Substituted Pyridine, Pyridazine, Pyrazine And Pyrimidine Compounds And Methods For Using The Same
Carboxamide Compounds And Methods For Using The Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
Ampk-Activating Heterocyclic Compounds and Methods for Using the Same
2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
Mode of Action Screening Method
In Vivo Reporter System
Methods for Using Carboxamide, Sulfonamide and Amine Compounds
Methods for Using Carboxamide, Sulfonamide and Amine Compounds
Method for Making Macrocycles
Whole Blood Assay for Measuring Ampk Activation
Synthesis of Polycyclic Alkaloids
Synthesis of Polycyclic Alkaloids
Cyclopropyl Mida Boronate
Cyclopropyl Pida Boronate
Cyclopropyl MIDA Boronate
Treatment for Vitiligo
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Protein Kinase C Inhibitors and Uses Thereof
Xinafoate Salt of N4-(2,2-Difluoro-4H-BENZ0 [1,4] Oxazin-3-One) -6-Yl] -5-Fluoro-N2- [3-(Methylaminocar Bonylmethyleneoxy) Phenyl] 2,4-Pyrimidinediamine
2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use
GDF-8 Inhibitors
(Trimethoxyphenylamino) Pyrimidinyl Formulations
(Trimethoxyphenylamino) Pyrimidinyl Formulations
Topical Formulation for Administering a Compound
Patent:
47,034 →
Application:
15/604,502 →
Protein Kinase C Inhibitors and Uses Thereof
Pharmaceutical Process and Intermediates
Pharmaceutical Process and Intermediates
Ubiquitination Inhibitors
Fused Imidazole Derivatives as TGF-Beta Inhibitors
Direct Ampk Activators
Application:
17/500,681 →
Publication:
US US20220098175A1
TGF-Beta Inhibitors
TGF-Beta Inhibitors
Pyrazole Compounds and Method for Making and Using the Compounds
Irak Inhibitors and Method for Making and Using
Pyrazole Compounds and Method for Making and Using the Compounds
Pyrazole Compounds and Method for Making and Using the Compounds
Pyrazole Compounds and Methods for Making and Using the Compounds
Irak Inhibitors and Method for Making and Using
Irak Inhibitors and Method for Making and Using
Irak Inhibitors and Method for Making and Using
Pyrazole Compounds and Method for Making and Using the Compounds
Application:
18/963,039 →
Publication:
US US20250326778A1
TGF-ß InhibitorC
TGF-ß INHIBITORU
TGF-ß INHIBITORS
Benzazole Compounds and Methods for Making and Using the Compounds
Benzazole Compounds and Methods for Making and Using the Compounds
Benzazole Compounds and Methods for Making and Using the Compounds
Benzazole Compounds and Methods for Making and Using the Compounds
Nrf2 Activating Compounds and Uses Thereof
Nrf2 Activating Compounds and Uses Thereof
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
Tyrosine Kinase Inhibitors
2,4-Diamino-Pyrimidine Compounds and Method for Making and Using the Compounds
2,4-Diamino-Pyrimidine Compounds and Method for Making and Using the Compounds
2,4-Diamino-Pyrimidine Compounds and Method for Making and Using the Compounds
Application:
17/988,062 →
Publication:
US US20230095835A1
Amide Compounds and Method for Making and Using
Amide Compounds and Method for Making and Using
Amide Compounds and Method for Making and Using
Amide Compounds and Method for Making and Using
Kinase Inhibitors and Methods for Making and Using
Kinase Inhibitors and Methods for Making and Using
Kinase Inhibitors and Methods for Making and Using
Application:
17/341,817 →
Publication:
US US20210309655A1
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds and/or Formulations
Method for Treating a Disease or Condition Using a Pyrazole Compound or Formulation Thereof
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds and/or Formulations
Method for Treating a Disease or Condition Using a Pyrazole Compound or Formulation Thereof
Application:
19/238,300 →
Publication:
US US20260124190A1
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Application:
96/050,074 →
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Application:
18/890,094 →
Publication:
US US20250034100A1
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Compounds and Method for Treating Cytokine Release Syndrome
Application:
17/592,779 →
Publication:
US US20220249475A1
Method of Blocking or Ameliorating Cytokine Release Syndrome
Application:
17/665,880 →
Publication:
US US20220152065A1
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Application:
17/843,194 →
Publication:
US US20230112865A1
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Application:
18/621,266 →
Publication:
US US20240368119A1
RIP1K Inhibitors
RIP1K Inhibitors
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Application:
18/334,608 →
Publication:
US US20230322732A1
Heterocyclic RIP1 Kinase Inhibitors
Heterocyclic RIP1 Kinase Inhibitors
Heterocyclic RIP1 Kinase Inhibitors
Method for Treatment of Covid-19-Associated Conditions
RIP1K Inhibitors
RIP1K Inhibitors
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
Heterocyclic RIP1 Inhibitory Compounds
Heterocyclic RIP1 Inhibitory Compounds
Application:
18/899,350 →
Publication:
US US20250092057A1
Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus
Application:
18/690,705 →
Publication:
US US20240382470A1
Crystalline Forms of a RIPK1 Inhibitor
Application:
18/711,541 →
Publication:
US US20250019372A1
Tricyclic Irak Inhibitors
Bicyclic Inhibitors of Irak
Application:
18/204,304 →
Publication:
US US20230391748A1
Pyrimid-2-Yl-Pyrazole Compounds as Irak Inhibitors
Pyrimid-2-Yl-Pyrazole Compounds as Irak Inhibitors
Application:
19/262,001 →
Publication:
US US20250333408A1
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
Application:
18/383,827 →
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
Inhibiting Mutant Idh-1
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
Treating Patients Harboring an Isocitrate Dehydrogenase-1 (Idh-1) Mutation
Inhibiting Mutant Idh-1
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
Treating Patients Harboring an Isocitrate Dehydrogenase 1 (Idh-1) Mutation
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
Treating Patients Harboring an Isocitrate Dehydrogenase-1 (Idh-1) Mutation
Application:
19/041,868 →
Publication:
US US20260000664A1
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
Application:
19/040,808 →
Publication:
US US20260014138A1
Inhibiting Mutant Idh-1
Application:
19/078,066 →
Publication:
US US20260060975A1
Solid Forms of ((S)-5-((1-(6-Chloro-2-Oxo-1,2-Dihydroquinolin-3-Yl)Ethyl)Amino)-1-Methyl-6-Oxo-1,6-Dihydropyridine-2-Carbonitrile
Solid Forms of ((S)-5-((1-(6-Chloro-2-Oxo-1,2-Dihydroquinolin-3-Yl)Ethyl)Amino)-1-Methyl-6-Oxo-1,6-Dihydropyridine-2-Carbonitrile
Solid Forms of ((S)-5-((1-(6-Chloro-2-Oxo-1,2-Dihydroquinolin-3-Yl)Ethyl)Amino)-1-Methyl-6-Oxo-1,6-Dihydropyridine-2-Carbonitrile
Solid Forms of ((S)-5-((1-(6-Chloro-2-Oxo-1,2-Dihydroquinolin-3-Yl)Ethyl)Amino)-1-Methyl-6-Oxo-1,6-Dihydropyridine-2-Carbonitrile
Solid Forms of ((S)-5-((1-(6-Chloro-2-Oxo-1,2-Dihydroquinolin-3-Yl)Ethyl)Amino)-1-Methyl-6-Oxo-1,6-Dihydropyridine-2-Carbonitrile
Application:
18/752,726 →
Publication:
US US20250161292A1
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH1)
Patent:
11,566,013 →
Application:
16/953,112 →
Use of a Syk Inhibitor for the Treatment of Chemical or Radiation Induced Lung Injury
Application:
19/161,212 →
Use of a Syk Inhibitor for the Treatment of Sickle Cell Disease
Application:
19/161,211 →
Publication:
US US20260199364A1
Formulations and Dosing Regimens for RIP1 Kinase Inhibitors for Treating Autoimmune and Inflammatory Diseases
Application:
63/510,196 →
Formulations and Dosing Regimens for RIP1 Kinase Inhibitors for Treating Autoimmune and Inflammatory Diseases
Application:
18/745,814 →
Publication:
US US20250000872A1
Treatment of Acute Myeloid Leukemia with Olutasidenib, Venetoclax and a Hypomethylating Agent
Application:
19/499,807 →
Treatment of Cns Tumors with Olutasidenib and Temozolomide
Application:
19/068,996 →
Publication:
US US20250275956A1
Inhibitors of Ret
Inhibitors of Ret
Inhibitors of Ret
Inhibitors of Ret
Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration
Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration
Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration
Ret Inhibitor for Use in Treating Cancer Having a Ret Alteration
Pralsetinib Pharmaceutical Compositions
Solid Forms of Pralsetinib
Solid Forms of Pralsetinib
Application:
19/327,837 →
Publication:
US US20260109685A1
Method of Preparing Pralsetinib
Application:
18/255,402 →
Publication:
US US20240059672A1
Solid Forms of 1-(4-(4-((3-(3,6-Difluoropyridin-2-Yl)-1-((1R,4R)-4-Ethoxycyclohexyl)-1H-Pyrazol-4-Yl)Carbamoyl)Thiazol-2-Yl)-1H-Pyrazol-1-Yl)Ethyl Phosphate and Salts Thereof, and Their Pharmaceutical Compositions and Uses
Application:
19/411,088 →
Publication:
US US20260159538A1
Methods of Treatment
Application:
19/198,985 →
Publication:
US US20260158048A1
Pharmaceutical Compositions
Application:
19/410,904 →
Publication:
US US20260157970A1
GDF-8 Inhibitors
Methods of Treating Cell Proliferative Disorders
PCT:
PCT/US2007/064511 ↗
Wet Granulation Using a Water Sequestering Agent
PCT:
PCT/US2008/082618 ↗
Use of 2,4-Pyrimidinediamines for the Treatment of Atherosclerosis
PCT:
PCT/US2009/034718 ↗
Synthesis of 2,4-Pyrimidinediamines
PCT:
PCT/US2010/040792 ↗
Pharmaceutical Process and Intermediates
PCT:
PCT/US2014/071613 ↗
Pyrazole Compounds and Method for Making and Using the Compounds
PCT:
PCT/US2016/028957 ↗
Irak Inhibitors and Method for Making and Using
PCT:
PCT/US2017/058339 ↗
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds and/or Formulations
PCT:
PCT/US2020/048528 ↗
A Method for Treating a Disease or Condition Using a Pyrazole Compound or Formulation Thereof
PCT:
PCT/US2022/018432 ↗
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
PCT:
PCT/US2019/030473 ↗
Compounds and Method for Treating Cytokine Release Syndrome
PCT:
PCT/US2020/045402 ↗
Method of Blocking or Ameliorating Cytokine Release Syndrome
PCT:
PCT/US2020/046060 ↗
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
PCT:
PCT/US2020/049487 ↗
RIP1K Inhibitors
PCT:
PCT/US2021/025598 ↗
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
PCT:
PCT/US2020/049451 ↗
Heterocyclic RIP1 Kinase Inhibitors
PCT:
PCT/US2020/049540 ↗
Heterocyclic RIP1 Kinase Inhibitors
PCT:
PCT/US2022/019744 ↗
Method for Treatment of Covid-19-Associated Conditions
PCT:
PCT/US2021/021951 ↗
RIP1K Inhibitors
PCT:
PCT/US2021/039112 ↗
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
PCT:
PCT/US2020/049527 ↗
Heterocyclic RIP1 Inhibitory Compounds
PCT:
PCT/US2020/059348 ↗
Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated with Infection by a Respiratory Virus
PCT:
PCT/US2022/041718 ↗
Method for Treatment of an Excessive Immunological Response to an Infection by a Respiratory Virus
PCT:
PCT/US2022/041721 ↗
Crystalline Forms of a RIPK1 Inhibitor
PCT:
PCT/US2022/052072 ↗
Bicyclic Inhibitors of Irak
PCT:
PCT/US2023/024063 ↗
Pyrimid-2-Yl-Pyrazole Compounds as Irak Inhibitors
PCT:
PCT/US2023/015889 ↗
Pyridin-2(1H)-One Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
PCT:
PCT/US2015/051055 ↗
Inhibiting Mutant Idh-1
PCT:
PCT/US2019/032747 ↗
Use of a Syk Inhibitor for the Treatment of Chemical or Radiation Induced Lung Injury
PCT:
PCT/US2024/018227 ↗
Use of a Syk Inhibitor for the Treatment of Sickle Cell Disease
PCT:
PCT/US2024/018228 ↗
Formulations and Dosing Regimens for RIP1 Kinase Inhibitors for Treating Autoimmune and Inflammatory Diseases
PCT:
PCT/US2024/034380 ↗
Treatment of Hematologic Malignancies or Pre-Malignancies
PCT:
PCT/US2024/036827 ↗
Treatment of Cns Tumors with Olutasidenib and Temozolomide
PCT:
PCT/US2025/018173 ↗
Pralsetinib Pharmaceutical Compositions
PCT:
PCT/US2021/034811 ↗
Solid Forms of Pralsetinib
PCT:
PCT/US2021/034823 ↗
Method of Preparing Pralsetinib
PCT:
PCT/US2021/061754 ↗
Solid Forms of 1-(4-(4-((3-(3,6-Difluoropyridin-2-Yl)-1-((1R,4R)-4-Ethoxycyclohexyl)-1H-Pyrazol-4-Yl)Carbamoyl)Thiazol-2-Yl)-1H-Pyrazol-1-Yl)Ethyl Phosphate and Salts Thereof, and Their Pharmaceutical Compositions and Uses
PCT:
PCT/US2025/058337 ↗
Methods of Treatment
PCT:
PCT/US2025/027682 ↗
Pharmaceutical Compositions
PCT:
PCT/US2025/058279 ↗
Related Assignments
(20)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 29, 2004
From: RAMESH, USHA V.; LOOK, GARY CHARLES; SINGH, RAJINDER; ISSAKANI, SARKIZ D.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 015624/0606 →
Assignment of Assignor's Interest
Nov 1, 2004
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD G.; CLOUGH, JEFFREY
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 015937/0587 →
Assignment of Assignor's Interest
Dec 3, 2004
From: LORENS, JAMES B.; ATCHISON, ROBERT E.; FRIERA, ANNABELLE; HOLLAND, SACHA
To: RIGEL PHARMACEUTICALS, INCORPORATED
Reel/Frame 015425/0299 →
Assignment of Assignor's Interest
Jan 14, 2005
From: SINGH, RAJINDER; ARGADE, ANKUSH; LI, HUI; BHAMIDIPATI, SOMASEKHAR
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 015598/0939 →
Assignment of Assignor's Interest
Jan 21, 2005
From: SINGH, RAJINDER; LI, HUI
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 015611/0890 →
Assignment of Assignor's Interest
Mar 21, 2005
From: SINGH, RAJINDER; RAMESH, USHA; ISSAKANI, SARKIZ D.; LOOK, GARY CHARLES
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 016378/0352 →
Assignment of Assignor's Interest
May 17, 2005
From: GOFF, DANE; SINGH, RAJINDER; LU, HENRY
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 016584/0286 →
Assignment of Assignor's Interest
Aug 12, 2005
From: THOTA, SAMBAIAH; SINGH, RAJINDER; LAIDIG, GUY; LU, HENRY
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 016877/0978 →
Confirmation of Exclusive Patent License
Aug 15, 2005
From: RIGEL PHARMACEUTICALS, INC.
To: PFIZER INC.
Reel/Frame 016888/0112 →
Assignment of Assignor's Interest
Sep 26, 2005
From: KINSELLA, TODD M.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 016584/0567 →
Assignment of Assignor's Interest
Oct 19, 2005
From: LI, HUI; ARGADE, ANKUSH; SINGH, RAJINDER; THOTA, SAMBAIAH
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 016661/0110 →
Assignment of Assignor's Interest
Nov 7, 2005
From: LI, HUI; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 016743/0351 →
Assignment of Assignor's Interest
Apr 17, 2006
From: LI, HUI
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 017481/0151 →
Assignment of Assignor's Interest
Apr 20, 2007
From: CLOUGH, JEFFREY WAYNE; BHAMIDIPATI, SOMASEKHAR; SINGH, RAJINDER; MASUDA, ESTEBAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 019188/0184 →
Assignment of Assignor's Interest
Mar 30, 2010
From: CLOUGH, JEFFREY WAYNE; BHAMIDIPATI, SOMASEKHAR; SINGH, RAJINDER; MASUDA, ESTEBAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 024159/0050 →
Assignment of Assignor's Interest
Mar 22, 2011
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD; MOLINEAUX, SUSAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 025997/0082 →
Corrective Assignment to Correct the Assignor: Zhao, Haoran Doc Date: 04/05/2007 Previously Recorded on Reel 024159 Frame 0050. Assignor(S) Hereby Confirms the Assignment.
Jul 30, 2012
From: CLOUGH, JEFFREY WAYNE; BHAMIDIPATI, SOMASEKHAR; SINGH, RAJINDER; MASUDA, ESTEBAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 028680/0744 →
Assignment of Assignor's Interest
Oct 23, 2018
From: YU, JIAXIN; BHAMIDIPATI, SOMASEKHAR; HOLLAND, SACHA; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 047292/0814 →
Assignment of Assignor's Interest
Nov 18, 2021
From: YU, JIAXIN; BHAMIDIPATI, SOMASEKHAR; HOLLAND, SACHA; SINGH, RAJINDER
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 058739/0253 →
Security Interest
Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →